Headache therapy with botulinum toxin: Form over substance

Archives of Neurology

Volumn 65, Issue 1, 2008, Pages 149-151

  Pakalnis, Ann ^a   Couch, James ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; NON PRESCRIPTION DRUG;

BLEPHAROSPASM; CHRONIC DAILY HEADACHE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DYSTONIA; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; MIGRAINE; NEUROLOGIC DISEASE; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; STRABISMUS; TENSION HEADACHE;

BOTULINUM TOXINS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; HEADACHE; HUMANS; MIGRAINE DISORDERS;

EID: 38349048521     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2007.21     Document Type: Review

References (18)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. JAMA. 1992;267(1):64-69.
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004;24(suppl 1):9-160.
3. Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headaches in the general population. Headache. 1999;39(3):190-196.
4. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors, and biannual follow-up. Neurology. 2000;54(2):314-319.
5. Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls. Cephalalgia. 2005;25(2):124-131.
6. Dutton J, Fowler A. Botulinum toxin in ophthalmology. Surv Ophthalmol. 2007;52(1):13-31.
7. Smuts J, Schultz D, Banard A. Mechanism of action of botulinum toxin type-a in migraine prevention: a pilot study. Headache. 2004;44(8):801-805.
8. Klein AW. Complications and adverse reactions with the use of botulinum toxin. Dis Mon. 2002;48(5):336-356.
9. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146-S168.
10. Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord. 1987;2(4):237-254.
11. Binder WJ, Brin MF, Blitzer A, Schoenrock LB, Pogoda JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123(6):669-676.
12. Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment: for the Botox Migraine Clinical Research Group. Headache. 2000;40(6):445-450.
13. Evers S, Vollmen-Haase J, Schwaag S, Rahmann A, Husstedt IW, Frese A. Botulinum toxin type A in the prophylactic treatment of migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004;24(10):838-843.
14. Aurora S, Gawel M, Brandes J, Pokta S, Vandenburgh A; Botox North American Episodic Migraine Study Group. Botulinum toxin type A prophylactic treatment of episodic migraine: a randomized, double-blind, placebo controlled exploratory study. Headache. 2007;47(4):489-499.
15. Relja A, Poole A, Schoenen J, Pascual J, Lei X, Thompson C; European BoNTA Headache Study Group. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia. 2007;27(6):492-503.
16. Dodick D, Mauscop A, Elkind A, DeGryse R, Brin M, Silberstein S; Botox CDH Study Group. Botulinum toxin type A for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo controlled study. Headache. 2005;45(4):315-324.
17. Mathew N, Frishberg B, Gawel M, Dimitrova R, Gibson J, Turkel C; Botox CDH Study Group. Botulinum toxin type A (Botox) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005;45(4):293-307.
18. Silberstein S, Gobel H, Jensen K, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006;26(7):790-800.